Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.EMD Serono amends deal with Opexa for multiple sclerosis drug Tcelna
Under the deal, EMD Serono will pay Opexa additional $3m to support the ongoing Phase IIb clinical trial (Abili-T Trial) in patients with secondary progressive MS (SPMS). The
Under the deal, EMD Serono will pay Opexa additional $3m to support the ongoing Phase IIb clinical trial (Abili-T Trial) in patients with secondary progressive MS (SPMS). The
The deal will see Recro Pharma secure worldwide rights to IV/IM meloxicam and also a contract manufacturing facility, royalty and formulation business in Gainesville, Georgia, US. IV/IM meloxicam
The deal will see advancement of an alternative delivery method for Pfenex’s Px563L-mrPA, using Glide’s solid dose formulation technology. The contract extension is the result of the National
RGN-259 is a sterile, preservative-free topical eye drop for ophthalmic indications whose active ingredient is Thymosin beta 4 (TB4). The company will receive a $5.92m investment from Global
Under the deal, Concordia will buy substantially all of the commercial assets of Covis Pharma and Covis Injectables, including 18 branded and authorized generic products. Covis drug portfolio
The companies will conduct a study assess the clinical accuracy of spectral imaging technology with low radiation dose to measure breast density, potentially increasing accuracy of cancer detection
The anti-blood clotting drug apixaban can be used to treat venous thromboembolism (VTE) in adults, which is used to describe deep vein thrombosis (DVT) and pulmonary embolism (PE).
Developed by Seattle-based non-profit organization Sage Bionetworks and part of the Accelerating Medicines Partnership (AMP), the AMP-AD Knowledge Portal will help in sharing and analysis of large and
People familiar with the matter were reported by Reuters as saying that GSK confirmed the dismissal was for wrongdoing and misconduct that took place before mid-2013. However, the
The prodrug for isavuconazole, Cresemba has been approved for use in patients aged 18 years and above in the treatment of zygomycosis, which are life-threatening fungal infections predominantly